secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001370053-23-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis
--------------------------------------------------------------------------------

- Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.
- Cash and investments totaled $526.1M; reiterated cash runway through year-end 2026.
- Completed $50M stock repurchase program authorized in January 2023.
- Initiated global Phase 2b trial for ANB032 (BTLA agonist) in moderate-to-severe atopic dermatitis; top-line data expected by year-end 2024.
- Plans to start Phase 2b trial for rosnilimab in rheumatoid arthritis in Q3 2023 and second Phase 2 trial by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/0001370053-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000039/anab-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer